<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029480</url>
  </required_header>
  <id_info>
    <org_study_id>8835-059</org_study_id>
    <secondary_id>MK-8859-059</secondary_id>
    <secondary_id>PHRR190913-002184</secondary_id>
    <nct_id>NCT04029480</nct_id>
  </id_info>
  <brief_title>Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)</brief_title>
  <official_title>A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (Ages 10 to 17 Years, Inclusive) With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric
      participants with T2DM on metformin with/without insulin. The primary hypothesis of the study
      is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition
      of placebo after 24 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">July 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Hemoglobin A1C (HbA1C) at 24 weeks (pooled ertugliflozin 5 mg and 15 mg versus placebo)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples are collected at baseline and Week 24 to determine the least squares mean HbA1C change from baseline (i.e., HbA1C at Week 24 minus HbA1C at baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience an Adverse Event (AE)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience an AE</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinue Study Treatment Due to an AE</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinue Study Treatment Due to an AE</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin A1C at Week 24 (dose-optimized ertugliflozin versus placebo)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples are collected at baseline and Week 24 to determine the least squares mean HbA1C change from baseline (i.e., HbA1C at Week 24 minus HbA1C at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin A1C at Week 24 (ertugliflozin 5 mg versus placebo)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples are collected at baseline and Week 24 to determine the least squares mean HbA1C change from baseline (i.e., HbA1C at Week 24 minus HbA1C at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Plasma Glucose (FPG) at 24 Weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Blood glucose is measured on a fasting basis. FPG is expressed as mg/dL. Blood is drawn at predose on Day 1 and after 24 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 24 minus FPG at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin A1C at 54 Weeks</measure>
    <time_frame>Baseline and 54 weeks</time_frame>
    <description>Hemoglobin A1C is a measure of the percentage of glycated HbA1C in the blood. Participant whole blood samples are collected at baseline and Week 54 to determine the least squares mean HbA1C change from baseline (i.e., HbA1C at Week 54 minus HbA1C at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in FPG at 54 Weeks</measure>
    <time_frame>Baseline and 54 weeks</time_frame>
    <description>Blood glucose is measured on a fasting basis. FPG is expressed as mg/dL. Blood is drawn at predose on Day 1 and after 54 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 54 minus FPG at baseline).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg/5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will initially receive ertugliflozin (ERTU) 5 mg once daily (QD) and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at Week 12 (WK12), all participants that do not meet the up-titration criteria will remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54. Approximately half the participants who meet the up-titration criteria at the second randomization at WK12 will also remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54.
Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a fasting fingerstick glucose (FFSG) of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg/15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will initially receive ERTU 5 mg QD and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at WK12, approximately half the participants who meet the up-titration criteria at the second randomization will up-titrate to ERTU 15 mg and placebo to ERTU 5 mg from WK12 to WK54.
Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a FFSG of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At the first randomization, participants receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD for 12 weeks. Participants in the placebo group with HbA1C ≥7.0% (53 mmol/mol) at WK12 will be mock titrated. Note: The up-titration criteria for participants on insulin will include a FFSG of ≥110 mg/dL (6.1 mmol/L) in addition to HbA1C ≥7.0% (53 mmol/mol) at WK12. Participants will continue to receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD from WK24 to WK54. Participants will remain on their background metformin with/without insulin treatment throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 5 mg</intervention_name>
    <description>Ertugliflozin 5 mg, oral, 1 tablet QD</description>
    <arm_group_label>Ertugliflozin 5 mg/15 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg/5 mg</arm_group_label>
    <other_name>MK-8835</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 15 mg</intervention_name>
    <description>Ertugliflozin 15 mg, oral, 1 tablet QD</description>
    <arm_group_label>Ertugliflozin 5 mg/15 mg</arm_group_label>
    <other_name>MK-8835</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to ertugliflozin 15 mg, oral, 1 tablet QD</description>
    <arm_group_label>Ertugliflozin 5 mg/5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to ertugliflozin 5 mg, oral, 1 tablet QD</description>
    <arm_group_label>Ertugliflozin 5 mg/15 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.</description>
    <arm_group_label>Ertugliflozin 5 mg/15 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg/5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants will receive stable dose of background metformin.</description>
    <arm_group_label>Ertugliflozin 5 mg/15 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg/5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has diabetes diagnosed by one of the American Diabetes Association (ADA) criteria.

          2. Has body mass index (BMI) ≥85th percentile at screening OR participant has a history
             of being overweight or obese at time of diagnosis of Type 2 diabetes mellitus (T2DM).

          3. T2DM for ≥2 years, OR T2DM for &lt;2 years and a fasting C-peptide value &gt;0.6 ng/mL at
             Screening.

          4. On stable metformin monotherapy (≥1500 mg/day, for ≥8 weeks prior to Screening, OR on
             a stable metformin dose (≥1500 mg/day, for ≥8 weeks prior to Screening and a stable
             dose of insulin for ≥8 weeks prior to Screening.

          5. Contraceptive use by male participants should be consistent with local regulations
             regarding the methods of contraception for those participating in clinical studies.

          6. Is a non-sterilized female who is currently not sexually active OR who agrees to
             abstain from heterosexual activity OR who agrees to start contraception prior to
             initiating sexual activity and who agrees to use an adequate method of contraception.
             Contraceptive use by females should be consistent with local regulations regarding the
             methods of contraception for those participating in clinical studies.

          7. Have a family member or adult who, along with the participant, will be closely
             involved in the participant's daily activities (in the opinion of the investigator)
             and in the participant's treatment and study procedures.

        Exclusion Criteria:

          1. Has known type 1 diabetes mellitus or documented evidence of positive diabetes
             autoantibodies performed when participant was diagnosed with diabetes.

          2. Has known monogenic diabetes, or secondary diabetes.

          3. Has symptomatic hyperglycemia and/or moderate to large ketonuria requiring immediate
             initiation of another antihyperglycemic agent, including insulin.

          4. Has a known hypersensitivity or intolerance to any sodium glucose co-transporter 2
             (SGLT2) inhibitor.

          5. Is pregnant, or breast feeding or is expecting to conceive or donate eggs during the
             study, including 14 days following the last dose of study medication.

          6. Has previously taken an SGLT2 inhibitor (such as canagliflozin, dapagliflozin,
             empagliflozin, or ertugliflozin) or was enrolled in a study for these agents.

          7. Has a history of idiopathic acute pancreatitis or chronic pancreatitis.

          8. Has a history of severe hypoglycemia while on insulin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham ( Site 2207)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-1711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-638-5031</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Los Angeles ( Site 2201)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-361-6327</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center of Excellence in Diabetes and Endocrinology ( Site 2203)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>916-570-2750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joe Dimaggio Children's Hospital ( Site 2217)</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-265-6388</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICCT Research International, Inc. ( Site 2211)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60659</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-988-4500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barry J. Reiner MD LLC ( Site 2204)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-646-4009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital ( Site 2219)</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>248-898-4578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHEAR Center LLC ( Site 2200)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>347-270-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia ( Site 2205)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>267-426-9218</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Endocrinology and Associates PA ( Site 2218)</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-693-0904</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc ( Site 2300)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3227641370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre ( Site 0002)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5196858138</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0001)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514-240-9620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro De Diabetes Cardiovascular IPS Ltda ( Site 0101)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5753780646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedPlus Medicina Prepagada S.A. ( Site 0102)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+575226772</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Los Yoses ( Site 0200)</name>
      <address>
        <city>San Jose</city>
        <zip>11501</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50622536440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Dr. Robert Reid Cabral ( Site 0300)</name>
      <address>
        <city>Santo Domingo</city>
        <state>Distrito Nacional (Santo Domingo)</state>
        <zip>10101</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8299124020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU du BOCAGE ( Site 0407)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33380295753</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consultorio Privado Dr. Geraldine Utrilla ( Site 0501)</name>
      <address>
        <city>Chiquimula</city>
        <zip>20001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50279323397</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endopedia ( Site 0503)</name>
      <address>
        <city>Guatemala</city>
        <zip>01009</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50253166777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinicas Las Americas ( Site 0502)</name>
      <address>
        <city>Guatemala</city>
        <zip>01014</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50240347015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem Klinikai Kozpont Gyermekgyogyaszati Klinika ( Site 0708)</name>
      <address>
        <city>Pecs</city>
        <state>Baranya</state>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3672535900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0705)</name>
      <address>
        <city>Gyula</city>
        <state>Bekes</state>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36202650065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 0701)</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36709403149</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szabolcs Szatmar Bereg Megyei Korhazak es Egyetemi Oktato korhaz ( Site 0704)</name>
      <address>
        <city>Nyiregyhaza</city>
        <state>Szabolcs-Szatmar-Bereg</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36204583828</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 0702)</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36309770577</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem II. sz. Gyermekgyogyaszati Klinika ( Site 0703)</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36208259258</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center ( Site 0802)</name>
      <address>
        <city>Beer Sheva</city>
        <state>HaDarom</state>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97286403158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Armon M.C ( Site 0803)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3350121</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972507483453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0801)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247771606</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Edmond and Lily Safra Children s Hospital ( Site 0804)</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tell Abib</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235305015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Mount Scopus ( Site 0800)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9124001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97225844430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Meyer ( Site 0901)</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390555662486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS G. Gaslini ( Site 0900)</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393474038247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0903)</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390668593074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universiti Sains Malaysia ( Site 1102)</name>
      <address>
        <city>Kubang Kerian</city>
        <state>Kelantan</state>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6097673748</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Taiping ( Site 1104)</name>
      <address>
        <city>Taiping</city>
        <state>Perak</state>
        <zip>34000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6058204029</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang. ( Site 1101)</name>
      <address>
        <city>Georgetown</city>
        <state>Pulau Pinang</state>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6042225707</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre ( Site 1100)</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan Kuala Lumpur</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60379492065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Putrajaya ( Site 1103)</name>
      <address>
        <city>Putrajaya</city>
        <state>Wilayah Persekutuan Putrajaya</state>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60383145472</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion Clinica Cardiometabolica de Occidente ( Site 1007)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44150</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3336152650</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Medica de Occidente S.C. ( Site 1001)</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45116</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523312044280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 1003)</name>
      <address>
        <city>Madero</city>
        <state>Tamaulipas</state>
        <zip>89440</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+528332142554</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Atencion e Investigacion Clinica SC ( Site 1009)</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20129</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+524491000578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Diagnostico Medicont S.A. de C.V ( Site 1006)</name>
      <address>
        <city>Mexico City</city>
        <zip>11410</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525521583697</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAIMED Investigación en Salud S.A de C.V ( Site 1008)</name>
      <address>
        <city>Mexico</city>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525565834651</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiologia Total SAPI de CV ( Site 1004)</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5214424678724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Davao Doctors Hospital ( Site 1400)</name>
      <address>
        <city>Davao</city>
        <state>Davao Del Sur</state>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+63822853032</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Studies on Diabetes Foundation Inc. ( Site 1402)</name>
      <address>
        <city>Marikina</city>
        <state>Rizal</state>
        <zip>1810</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639998832018</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Visayas State University Medical Center ( Site 1401)</name>
      <address>
        <city>Iloilo</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639178476189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poradnia Chorob Metabolicznych. Centrum Zdrowia Tuchow ( Site 1500)</name>
      <address>
        <city>Wierzchoslawice</city>
        <state>Malopolskie</state>
        <zip>33-122</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48146535101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Medical Research Sp. z o.o. ( Site 1511)</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-156</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48604628659</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bashkir State Medical University Hospital ( Site 1603)</name>
      <address>
        <city>Ufa</city>
        <state>Baskortostan, Respublika</state>
        <zip>450083</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79173445910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution Endocrinological Research Center ( Site 1611)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79652359956</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's City Clinical Hospital #1 ( Site 1604)</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirskaya Oblast'</state>
        <zip>630048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79139546550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rostov Scientific Research Institution of Obstetrics and Pediatry ( Site 1606)</name>
      <address>
        <city>Rostov-on-Don</city>
        <state>Rostovskaya Oblast'</state>
        <zip>344012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79185475185</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samara City Pediatric Clinical Hospital n.a. N.N. Ivanova ( Site 1610)</name>
      <address>
        <city>Samara</city>
        <state>Samarskaya Oblast'</state>
        <zip>443079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79033026128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Pediatric Medical University ( Site 1600)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79213246266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University ( Site 1601)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79172555589</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siberian State Medical University ( Site 1602)</name>
      <address>
        <city>Tomsk</city>
        <state>Tomskaya Oblast'</state>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79138267424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Voronezh State Medical University named after N.N.Burdenko ( Site 1608)</name>
      <address>
        <city>Voronezh</city>
        <state>Voronezskaja Oblast'</state>
        <zip>394024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79102487738</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz Medical City - Al Ahsa ( Site 1730)</name>
      <address>
        <city>Al Ahsa</city>
        <state>Ar Riyad</state>
        <zip>31982</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+966509369714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdul Aziz Medical City - AlRiyadh ( Site 1700)</name>
      <address>
        <city>Riyadh</city>
        <state>Ar Riyad</state>
        <zip>11426</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+966504461425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdul Aziz Medical City - AlRiyadh ( Site 1705)</name>
      <address>
        <city>Riyadh</city>
        <state>Ar Riyad</state>
        <zip>11426</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+966504256585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Salman bin Abdulaziz hospital - Al Riyadh ( Site 1720)</name>
      <address>
        <city>Riyadh</city>
        <state>Ar Riyad</state>
        <zip>11564</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+966555832994</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Salman bin Abdulaziz hospital Al Riyadh ( Site 1710)</name>
      <address>
        <city>Riyadh</city>
        <state>Ar Riyad</state>
        <zip>11564</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+966505415062</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdul Aziz Medical City. National Guard Health Affairs ( Site 1715)</name>
      <address>
        <city>Jeddah</city>
        <state>Makkah Al Mukarramah</state>
        <zip>21423</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+966505693307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hera General Hospital ( Site 1725)</name>
      <address>
        <city>Mecca</city>
        <state>Makkah Al Mukarramah</state>
        <zip>24211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+966555501280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova Uni. Tip Fakultesi ( Site 2403)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905325169131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 2400)</name>
      <address>
        <city>Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905332590609</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Medical Institution Regional Children Clinical Hospital ( Site 1910)</name>
      <address>
        <city>Chernivtsi</city>
        <state>Chernivetska Oblast</state>
        <zip>58005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380372575676</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 1914)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380677923486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHI Regional Childrens Clinical Hospital ( Site 1908)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61093</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+ 380577773781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ukr Center of Endocrine Surgery and Transplatation MOH Ukraine ( Site 1903)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>01021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380 50 355 23 65</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Endocrinology and Metabolism n.a. Komissarenko ( Site 1905)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380444310285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odessa Regional Children Clinical Hospital ( Site 1912)</name>
      <address>
        <city>Odesa</city>
        <state>Odeska Oblast</state>
        <zip>65031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380 50 316 90 76</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vinnitsa Regional Endocrinology Dispensary, VNMU n.a. M.I.Pyrogov ( Site 1901)</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnytska Oblast</state>
        <zip>21010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380432611736</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dubai Diabetes Center ( Site 2002)</name>
      <address>
        <city>Dubai</city>
        <state>Dubayy</state>
        <zip>215252</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+971505415500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mediclinic City Hospital ( Site 2005)</name>
      <address>
        <city>Dubai</city>
        <state>Dubayy</state>
        <zip>505004</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+971569963556</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Al Jalila Children s Specialty Hospital ( Site 2004)</name>
      <address>
        <city>Dubai</city>
        <state>Dubayy</state>
        <zip>7662</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+971589466920</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thumbay Hospital ( Site 2001)</name>
      <address>
        <city>Ajman</city>
        <zip>4184</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+971507879619</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rashid Center For Diabetes and Research ( Site 2006)</name>
      <address>
        <city>Ajman</city>
        <zip>5166</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+971501823166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital (Whitechapel) ( Site 2100)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>E1 1FR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442034265000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Middlesex University Hospital ( Site 2104)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>TW7 6AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442083216017</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Dominican Republic</country>
    <country>France</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

